Evaluating Amorphous Calcium Carbonate in Postmenopausal Women

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effects of amorphous calcium carbonate (ACC) on bone mineral density (BMD) in postmenopausal women, comparing those receiving ACC alone to those receiving ACC in combination with Denosumab. Participants will be assigned to one of two arms based on their eligibility for Denosumab treatment. The study will involve a total of 205 subjects, with clinical visits scheduled throughout the study period to monitor BMD changes and overall health. The primary goal is to assess the effectiveness of ACC in improving bone health in this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Postmenopausal women who are 60 to 90 years of age.
2. With BMD T-score of lower than -2.5 at the lumbar spine or total hip and -4.0 or higher at both sites. Subject who also meet the following criteria:

   A arm:-Subject who meet National Health Insurance (NHI) reimbursement criteria for use of denosumab.

   B arm:-Subject who does not meet NHI reimbursement criteria for use of denosumab, or who is no willing to receive denosumab treatment during study period, even meet NHI reimbursement criteria.
3. Subject who are naïve to osteoporosis treatment or have received prior bisphosphonate treatment for less than 3 years and not within 12 months prior to screening visit.
4. A minimum of 2 evaluable lumbar vertebrae in the L1-L4 region and 1 evaluable hip (i.e., either the left or right side).
5. Willingness to limit additional Vitamin D3 intake to 400IU or 800IU per day during the study period.
6. Ability to complete the entire procedure and to comply with study instructions.
7. Will provide completed and signed written informed consent.

Exclusion Criteria:

1. Subjects who had conditions that influence bone metabolism (i.e., Paget's disease and osteomalacia).
2. Subject on other osteoporosis therapies, parathyroid hormone or its derivatives, corticosteroids, systemic hormone-replacement therapy, selective estrogen-receptor modulators, tibolone, calcitonin or calcitriol 6 weeks prior to screening visit.
3. Subjects had a serum 25-hydroxyvitamin D level of less than 12 ng/ml.
4. Subjects had a BMD T-score of less than -4.0 at the lumbar spine or total hip.
5. Subjects with any severe or more than two moderate vertebral fractures on spinal x-ray at screening visit.
6. Subject who plan to initiate a new bisphosphonate treatment during study period.
7. Known hypersensitivity to any component of the study drug product.
8. Participation in any other investigational study within 30 days prior to receiving study medication.
9. Any condition that in the opinion of the investigator would jeopardize the evaluation of efficacy or safety.

Where it's running

• Kaohsiung Chang Gung Memorial Hospital
  Kaohsiung City, Taiwan Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Digital Eye-assisted bone density guides site drilling for a single dental implant

  This study tests whether using the Digital Eye bone-density assessment to guide drilling improves primary implant stability in adults needing one dental implant in a healed premolar or molar site.

  Recruiting King Abdullah University Hospital · Irbid · NCT07899606

• Role of LH and hCG in adults being evaluated for endocrine disorders

  This study looks at whether levels of luteinizing hormone (LH) and hCG in adults undergoing endocrine evaluation relate to their disease presence and outcomes.

  Recruiting Copenhagen University Hospital at Herlev · Herlev · NCT07824102

• Micronutrient Enhancement for Development and Health in Adolescent Girls

  This study tests whether daily micronutrient supplements (MMS or MMS+), compared with weekly iron-folic acid, can improve school performance and growth in 10- to 18-year-old girls in rural Bangladesh.

  Recruiting Phase 3 Johns Hopkins Bloomberg School of Public Health · Rangpur City · NCT07695883

• Can a blood marker called lumican reveal hidden fragility in postmenopausal osteoporosis

  This study tests whether serum lumican levels can help identify hidden fragility risk in postmenopausal women beyond what bone density shows.

  Recruiting Kanuni Sultan Suleyman Training and Research Hospital · Küçükçekmece, Istanbul · NCT07677072

• Functional Muscle-Bone Incongruity Index: A look at muscle strength and bone health in adults

  This observational study tests a composite FKUI score using handgrip strength and hip/spine bone density to see if it better reflects musculoskeletal health than each measure alone in adults undergoing routine DXA.

  Recruiting Kanuni Sultan Suleyman Training and Research Hospital · Küçükçekmece, Istanbul · NCT07677033

• Vessel-X Bone Filling Container System for Vertebral Augmentation

  A new minimally invasive vertebral augmentation approach tests the Vessel-X device to see if it safely improves pain and function in people with osteoporotic vertebral compression fractures.

  Recruiting at 2 sites National Defense Medical Center, Taiwan · Taipei and 1 other locations · NCT07665424

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.